Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025Frontiers in ImmunologyOpen Access

Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMaria Anna SicilianoMDMaria D’ApolitoTGTeresa Del Giudice

Discussion

Loading...

Member takes

Overview

Systematic review evaluates immunotherapy efficacy in NSCLC by age and performance status, suggesting tailored strategies.

Key Points

  • ICIs significantly improved overall survival and progression-free survival versus chemotherapy in most subgroups.
  • Patients over 75 years showed no overall survival benefit from ICIs, indicating age-related efficacy variation.
  • Cemiplimab and combination regimens ranked highest for younger patients, highlighting different treatment effectiveness across ages.
  • Findings support tailored immunotherapy approaches based on individual patient characteristics like age and performance status.

Cite This Study

Siciliano et al. (2025) studied this question.

synapsesocial.com/papers/68d5bd72dc445aa9033b0e82https://doi.org/10.3389/fimmu.2025.1635056
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Perioperative immune checkpoint inhibitors in elderly patients with resectable NSCLC: a systematic review and meta-analysis2025
  2. 2Efficacy of immunotherapy in older patients with triple-negative breast cancer: a systematic review2025
  3. 3Age-related survival disparities in advanced renal cell carcinoma following immune checkpoint inhibitor adoption using SEER and meta-analysis2025
  4. 4Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis2025 · 2 citations
  5. 5Immunotherapy in older adults with gynecologic cancers: rethinking age as a limiting factor.2025